Contrary to its association with improved 5-year survival in primary melanomas, PDCD4 expression was not associated with survival differences in metastatic disease either within the total tumor or the nuclear compartment, Figure 2c, d (log-rank p = 0.63 and p = 0.52, respectively). This evidence concerns the gene PDCD4 and neoplasm.